- Stocks
- Healthcare
- NASDAQ: CORT

Price (delayed)

$24.05

Market cap

$2.82B

P/E Ratio

26.14

Dividend/share

N/A

EPS

$0.92

Enterprise value

$2.75B

The company's equity rose by 41% YoY and by 7% QoQ

Corcept Therapeutics's debt has decreased by 26% YoY and by 16% QoQ

The P/E is 60% less than the 5-year quarterly average of 65.6 but 35% more than the last 4 quarters average of 19.2

The quick ratio is up by 29% year-on-year but it is down by 6% since the previous quarter

What are the main financial stats of CORT

Market
Valuations
Earnings

Shares outstanding

117.31M

Market cap

$2.82B

Enterprise value

$2.75B

Price to earnings (P/E)

26.14

Price to book (P/B)

5.34

Price to sales (P/S)

7.84

EV/EBIT

21.43

EV/EBITDA

21.07

EV/Sales

7.76

Revenue

$353.87M

EBIT

$128.2M

EBITDA

$130.44M

Free cash flow

$150.73M

Per share
Balance sheet
Liquidity

EPS

$0.92

Free cash flow per share

$1.31

Book value per share

$4.5

Revenue per share

$3.07

TBVPS

$4.95

Total assets

$571.73M

Total liabilities

$48.39M

Debt

$2.55M

Equity

$523.34M

Working capital

$431.01M

Debt to equity

0

Current ratio

10.07

Quick ratio

9.83

Net debt/EBITDA

-0.56

Margins
Efficiency
Dividend

EBITDA margin

36.9%

Gross margin

98.4%

Net margin

30%

Operating margin

36.2%

Return on assets

20.7%

Return on equity

22.6%

Return on invested capital

31.2%

Return on capital employed

24.5%

Return on sales

36.2%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Corcept Therapeutics stock price performed over time

Intraday

0.71%

1 week

5.62%

1 month

-4.3%

1 year

89.52%

YTD

-8.07%

QTD

1.09%

How have Corcept Therapeutics's revenue and profit performed over time

Revenue

$353.87M

Gross profit

$348.29M

Operating income

$128.2M

Net income

$106.01M

Gross margin

98.4%

Net margin

30%

The gross profit is up by 16% year-on-year

The revenue rose by 15% year-on-year

Corcept Therapeutics's operating income has increased by 15% YoY but it has decreased by 3.4% from the previous quarter

CORT's net income is up by 13% YoY but it is down by 3.1% QoQ

What is Corcept Therapeutics's growth rate over time

What is Corcept Therapeutics stock price valuation

P/E

26.14

P/B

5.34

P/S

7.84

EV/EBIT

21.43

EV/EBITDA

21.07

EV/Sales

7.76

The P/E is 60% less than the 5-year quarterly average of 65.6 but 35% more than the last 4 quarters average of 19.2

The EPS has grown by 12% year-on-year but it has declined by 3.2% since the previous quarter

The stock's price to book (P/B) is 52% less than its 5-year quarterly average of 11.1 but 20% more than its last 4 quarters average of 4.4

The company's equity rose by 41% YoY and by 7% QoQ

CORT's P/S is 32% above its last 4 quarters average of 5.9 but 7% below its 5-year quarterly average of 8.4

The revenue rose by 15% year-on-year

How efficient is Corcept Therapeutics business performance

The return on equity has declined by 23% year-on-year and by 11% since the previous quarter

CORT's return on assets is down by 22% year-on-year and by 11% since the previous quarter

CORT's ROIC is down by 22% year-on-year and by 10% since the previous quarter

The return on sales has declined by 2.9% since the previous quarter

What is CORT's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for CORT.

How did Corcept Therapeutics financials performed over time

The company's total assets rose by 39% YoY and by 7% QoQ

The quick ratio is up by 29% year-on-year but it is down by 6% since the previous quarter

Corcept Therapeutics's debt is 100% lower than its equity

CORT's debt to equity has shrunk by 100% QoQ and by 100% YoY

The company's equity rose by 41% YoY and by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.